The osteoarthritis therapeutics market was valued at USD 9.92 Billion in 2025 driven by the rising prevalence of osteoarthritis across the 8 major markets. The market size is anticipated to grow at a CAGR of 8.70% during the forecast period of 2026-2035 to achieve a value of USD 22.85 Billion by 2035.
Base Year
Historical Period
Forecast Period
The growing aging population that is more prone to developing chronic joint conditions is a primary driver of the market.
The rising development of biologic drugs and the growing demand for new and effective pain management therapies are significant market trends.
The growth in clinical trials and robust regulatory support are poised to elevate the market value in the forecast period.
Compound Annual Growth Rate
8.7%
Value in USD Billion
2026-2035
*this image is indicative*
Millions of people are suffering from osteoarthritis, which is the most prevalent kind of arthritis. It happens due to damage to the protective cartilage that cushions the ends of the bones. Even though osteoarthritis can harm any joint, it frequently affects the hands, knees, hips, and spine. While the damage to joints cannot be undone, osteoarthritis symptoms can typically be controlled. The progression of the disease may be slowed down, and pain and joint function may be improved by staying active, maintaining a healthy weight, and taking specific therapies.
The increasing aging population that is more prone to developing chronic joint conditions is driving the growth of the osteoarthritis therapeutics market. The growing initiatives of investments from both private and government organizations are also favoring market expansion. Moreover, the rising demand for effective pain management therapies, increasing preference for regenerative medicine, and growing public awareness are poised to impact the market dynamics significantly.
Increasing Elderly Population to Fuel Market Growth
The growing geriatric population is a major factor influencing the market growth. It can be attributed to the high prevalence of bone-related conditions in older adults. It is common in older people to develop joint issues such as joint pain and discomfort while walking or exercising. The chances of developing osteoarthritis in women are more in comparison to men after the age of 50. According to WHO, 1 in every 6 people worldwide will be aged 60 years or above by 2030. By 2050, the world’s population of people aged 60 years and older will double (2.1 billion). Moreover, the number of individuals aged 80 years or older is expected to triple between 2020 and 2050 and is projected to reach 426 million. This data indicates that a rise in osteoarthritis cases is expected in the coming years which will directly contribute to the market growth.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
"Osteoarthritis Therapeutics Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Drug Class
Market Breakup by Doses Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth
Based on the drug class, the market is segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), other analgesics, corticosteroids, hyaluronic acid injections, and others. NSAIDs cover a major market share owing to their efficacy in reducing pain and inflammation. For managing mild to moderate cases of osteoarthritis, medications like ibuprofen and naproxen are commonly used by the patients. However, long-term use of NSAIDs is linked to gastrointestinal and cardiovascular side effects.
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is one of the leading markets for osteoarthritis therapeutics due to the high prevalence of the condition, a substantial aging population, and significant R&D investment. The availability of advanced biologic therapies, including TNF inhibitors, JAK inhibitors, and hyaluronic acid injections, also supports the growth of the market in the region. Moreover, the rising interest in stem cell therapy and platelet-rich plasma (PRP) treatments is likely to impact the market dynamics in the country.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
This French multinational pharmaceutical and healthcare company is one of the dominant players in the market for osteoarthritis treatments. The company offers a robust portfolio of nonsteroidal anti-inflammatory drugs (NSAIDs) and pain management products.
Bayer, headquartered in Leverkusen, Germany, is a leading pharmaceutical and biotechnology company. Bayer is focused on developing new formulations of pain relief medications that can be used to treat osteoarthritis symptoms.
British multinational consumer healthcare company Haleon is a significant player in the market, particularly in the over-the-counter (OTC) segment of the osteoarthritis treatment space. It offers a wide range of pain relief products and is actively investing in developing more advanced, long-acting topical treatments for osteoarthritis patients.
Japan-based Seikagaku Corporation specializes in the development and manufacturing of hyaluronic acid-based therapies, which are commonly used by knee osteoarthritis patients. The company is focused on collaborating with international partners to expand its global presence.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Bristol Myers Squibb, Ono Pharmaceutical, Novartis AG, Pfizer Inc., Assertio Holdings, Pacira Biosciences Inc., Anika Therapeutics Inc., and Bioventus LLC.
Brazil Osteoarthritis Therapeutics Market
Mexico Osteoarthritis Therapeutics Market
Japan Osteoarthritis Therapeutics Market
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Doses Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share